Acadia, Allergan extend drug discovery collaboration

March 21, 2012

Acadia Pharmaceuticals Inc. and Allergan Inc. will continue to collaborate on drug discovery and development of new therapeutics for glaucoma and other ophthalmic indications through March 2013 under the terms of an extension that adds a year to the research term originally established in March 2003.

San Diego-Acadia Pharmaceuticals Inc. and Allergan Inc. will continue to collaborate on drug discovery and development of new therapeutics for glaucoma and other ophthalmic indications through March 2013 under the terms of an extension that adds a year to the research term originally established in March 2003.

Acadia also has two other collaboration agreements with Allergan, which have led to clinical programs in the areas of glaucoma and chronic pain.

“We are pleased to extend our longstanding drug discovery collaboration with Allergan,” said Uli Hacksell, PhD, chief executive officer of Acadia. “This productive alliance has continued to lead to interesting discoveries, which we hope to be able to translate into potential new therapies for glaucoma and related ophthalmic conditions.”

During the extended term of the collaboration agreement, the parties will jointly pursue research in the area of ophthalmology. Allergan is entitled to license exclusively specified chemistry and related assets for development and commercialization. Acadia will receive research funding and is eligible to receive license fees and milestone payments upon the successful achievement of agreed-on clinical and regulatory objectives as well as royalties on future product sales, if any, worldwide.

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Content:

News